Source: Rare tumors. Unidade: FM
Subjects: NEOPLASIA ENDÓCRINA MÚLTIPLA, ESTUDOS RETROSPECTIVOS, METÁSTASE NEOPLÁSICA (DIAGNÓSTICO), PROLIFERAÇÃO CELULAR, ANTINEOPLÁSICOS (USO TERAPÊUTICO), CARCINOMA
ABNT
MUNHOZ, Rodrigo Ramella et al. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors, v. 5, n. 3, p. 135-139, 2013Tradução . . Disponível em: https://doi.org/10.4081/rt.2013.e39. Acesso em: 06 nov. 2024.APA
Munhoz, R. R., Rego, J. F. de M., Ferrari, A. R. de C., Braghiroli, M. I., Bariani, G. M., Hoff, P. M., et al. (2013). Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors, 5( 3), 135-139. doi:10.4081/rt.2013.e39NLM
Munhoz RR, Rego JF de M, Ferrari AR de C, Braghiroli MI, Bariani GM, Hoff PM, Costa FP, Pfiffer TEF, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas [Internet]. Rare tumors. 2013 ; 5( 3): 135-139.[citado 2024 nov. 06 ] Available from: https://doi.org/10.4081/rt.2013.e39Vancouver
Munhoz RR, Rego JF de M, Ferrari AR de C, Braghiroli MI, Bariani GM, Hoff PM, Costa FP, Pfiffer TEF, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas [Internet]. Rare tumors. 2013 ; 5( 3): 135-139.[citado 2024 nov. 06 ] Available from: https://doi.org/10.4081/rt.2013.e39